In this study, a rationally designed hydrogenator, Nap-Phe-Phe-Phe-Asp-Asp-Asp-Tyr-OH (NapY), was co-assembled with the FGFR2 inhibitor AZD4547 (AZD) to construct an FGFR2-responsive hydrogel, aiming to achieve precise targeted therapy for endometriosis...In vivo studies confirmed that compared with endometriosis model mice treated with free AZD, those treated with Gel Y/AZD exhibited significantly superior inhibitory effects on the growth and metastasis of ectopic lesions. It is anticipated that this research will expect to be applied in the clinical treatment of endometriosis in the near future.

P2, N=316, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Feb 2026

P2, N=90, Recruiting, Spanish Oncology Genito-Urinary Group | Active, not recruiting --> Recruiting

P2, N=90, Active, not recruiting, Spanish Oncology Genito-Urinary Group | Recruiting --> Active, not recruiting

P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jan 2027

P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jan 2027

P2, N=20, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026

In 21 patients who received erdafitinib after testing, the median progression-free survival is 7.5 months, and one patient with a ctDNA-exclusive FGFR alteration remained on erdafitinib for 33 months. Our results support clinical uptake of ctDNA FGFR testing in combination with tissue-based approaches in mUC.

Recovery studies in spiked human serum and urine samples yielded excellent results (95.7-104.8% recovery, RSD ≤ 3.65%), validating the sensor's real-world applicability. Importantly, the sensor offers scalable fabrication, requires no toxic reducing agents, and exhibits strong selectivity and long-term stability, making it a novel and sustainable platform for therapeutic drug monitoring, pharmacokinetics, and point-of-care diagnostics.

This has broadened the treatment landscape of the disease to include novel agents, such as antibody-drug conjugates (e.g., enfortumab vedotin) and targeted therapies, including the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib. Equally important is the standardization and timely implementation of FGFR3 testing in clinical practice to optimize treatment planning. This review addresses key considerations in FGFR3 testing in mUC and discusses how it can be routinely incorporated into clinical practice.

Furthermore, [68Ga]Ga-DOTA-cHW8 validated FGFR1 dynamic modulation during erdafitinib treatment in CDX and PDX models, establishing its efficacy for noninvasive UM treatment response assessment. This study reports a cyclic peptide-based radiotracer, [68Ga]Ga-DOTA-cHW8, for FGFR1 PET imaging in UM. Through rational design and preclinical validation in UM models, we establish its high specificity, favorable pharmacokinetics properties, and capability to monitor FGFR1 dynamics during targeted therapy.